Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vericel Corproation (VCEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vericel Corproation 64 SIDNEY STREET CAMBRIDGE MA 02139 USA

P: 800-556-0311 F: 617-588-5554

Description:

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States.

Key Statistics

Overview:

Market Capitalization, $K 750,337
Shares Outstanding, K 43,347
Annual Sales, $ 63,920 K
Annual Net Income, $ -17,290 K
Last Quarter Sales, $ 22,480 K
Last Quarter Net Income, $ -1,070 K
36-Month Beta 3.13
% of Insider Shareholders 4.70%
% of Institutional Shareholders 79.31%

Growth:

1-Year Total Return 150.51%
3-Year Total Return 713.27%
5-Year Total Return 375.35%
5-Year Revenue Growth 319,500.00%
5-Year Earnings Growth 97.25%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.02 on 11/06/18
Next Earnings Date 03/04/19
Earnings Per Share ttm -0.26
EPS Growth vs. Prev Qtr 83.33%
EPS Growth vs. Prev Year 87.50%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-20 on 10/16/13

VCEL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -42.03
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -17.39
Return-on-Assets (Before Tax) -11.24
Net Margin % N/A
Debt/Equity 0.14
Price/Sales 7.90
Price/Cash Flow N/A
Price/Book 8.12
Book Value/Share 2.21
Interest Coverage -14.58
Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar